European Journal of Vascular & Endovascular Surgery
Volume 33, Issue 5 , Pages 583-591 , May 2007

Diabetes Care for Patients with Peripheral Arterial Disease

  • M. Heikkinen

      Affiliations

    • Department of Vascular Surgery, Helsinki University Central Hospital, Helsinki, Finland
    • Corresponding Author InformationCorresponding author. M. Heikkinen, MD, PhD, Department of Vascular Surgery, Helsinki University Hospital, P.O. Box 340, 00029 Helsinki, HUS, Finland.
    • ,
  • M. Salmenperä

      Affiliations

    • Department of Anesthesiology, Helsinki University Central Hospital, Helsinki, Finland
    • ,
  • A. Lepäntalo

      Affiliations

    • Division of Hematology, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland
    • ,
  • M. Lepäntalo

      Affiliations

    • Department of Vascular Surgery, Helsinki University Central Hospital, Helsinki, Finland

,Accepted 30 January 2007.

References 

  1. Mayor S. Diabetes affects nearly 6% of the world's adults. BMJ. 2006;9:1191
  2. Marshall SM, Flyvbjerg A. Prevention and early detection of vascular complications of diabetes. BMJ. 2006;2:475–480
  3. Finnish Diabetes Association . Developement program for prevention of type 2 diabetes. Population Strategy 2003–2010. Tampere: Hermes Oy; 2003;
  4. Jonsson B. CODE-2 Advisory Board. Revealing the cost of Type II diabetes in Europe. Diabetologia. 2002;45:S5–S12
  5. Kulzer B. Diabetes mellitus: how important is it to measure the quality of life?. Dtsch Med Wochenschr. 2006;131(Suppl. 8):S259–S263
  6. Adlerberth AM, Rosengren A, Wilhelmsen L. Diabetes and long-term risk of mortality from coronary and other causes in middle-aged Swedish men. A general population study. Diabetes Care. 1998;21:539–545
  7. Muntner P, He J, Astor BC, Folsom AR, Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol. 2005;16:529–538
  8. Eason SL, Petersen NJ, Suarez-Almazor M, Davis B, Collins TC. Diabetes mellitus, smoking, and the risk for asymptomatic peripheral arterial disease: whom should we screen?. J Am Board Fam Pract. 2005;18:355–361
  9. Norgren L, Hiatt WR, Dormandy JA, Nehler M, Harris KA, Fowkes FGR, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease. Eur J Vasc Endovasc Surg. 2007;33(Suppl. I):S1–S75
  10. Nathan DM, Lachin J, Cleary P, Orchard T, Brillon DJ, Backlund JY, et al Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med. 2003;5:2294–2303
  11. Kallio M, Forsblom C, Groop PH, Groop L, Lepäntalo M. Development of new peripheral arterial occlusive disease in patients with type 2 diabetes during a mean follow-up of 11 years. Diabetes Care. 2003;26:1241–1245
  12. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, et al. Meta-analysis: glycosylated hemoglobin and CVD disease in diabetes mellitus. Ann Intern Med. 2004;21:421–431
  13. Muntner P, Wildman RP, Reynolds K, Desalvo KB, Chen J, Fonseca V. Relationship between HbA1c level and peripheral arterial disease. Diabetes Care. 2005;28:1981–1987
  14. Eskelinen E, Lepäntalo M, Hietala EM, Sell H, Kauppila L, Mäenpää I, et al. Lower limb amputations in Southern Finland in 2000 and trends up to 2001. Eur J Vasc Endovasc Surg. 2004;27:193–200
  15. Oyibo SO, Jude EB, Voyatzoglou D, Boulton AJM. Clinical characteristics of patients with diabetic foot problems: changing patterns of foot ulcer presentation. Pract Diabetes Int. 2002;19:10–12
  16. Jude EB, Boulton AJM. Diabetic foot. In:  Beard J,  Gawes P editor. Vascular and Endovascular Surgery. 3rd edn.. Elsevier Saunders; 2006;p. 118–137
  17. Virkkunen J, Heikkinen M, Lepäntalo M, Metsänoja R, Salenius JP, Finnvasc Study Group . Diabetes as an independent risk factor for early postoperative complications in critical limb ischemia. J Vasc Surg. 2004;40:761–767
  18. Chung J, Bartelson BB, Hiatt WR, Peyton BD, McLafferty RB, Hopley CW, et al. Wound healing and functional outcomes after infrainguinal bypass with reversed saphenous vein for critical limb ischemia. J Vasc Surg. 2006;43:1183–1190
  19. Houben AJ, Nieuwenhuijzen Kruseman AC, Bouhouch E, Slaaf DW, Schaper NC. Peripheral macro- and microcirculation in short-term insulin-dependent diabetes mellitus: the role of prostaglandins in early haemodynamic changes. Eur J Clin Invest. 1993;23:662–667
  20. Flynn MD, O'Brien IA, Corrall RJ. The prevalence of autonomic and peripheral neuropathy in insulin-treated diabetic subjects. Diabet Med. 1995;12:310–313
  21. Fowler B, Jamrozik K, Norman P, Allen Y. Prevalence of peripheral arterial disease: persistence of excess risk in former smokers. Aust N Z J Public Health. 2002;26:219–224
  22. Guerci B, Bohme P, Kearney-Schwartz A, Zannad F, Drouin P. Endothelial dysfunction and type 2 diabetes. Part 2: altered endothelial function and the effects of treatments in type 2 diabetes mellitus. Diabetes Metab. 2001;27(4 Pt 1):436–447
  23. The Diabetes Control and Complications Trial Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;30:977–986
  24. UK Prospective Diabetes Study (UKPDS) Group . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;12:837–853
  25. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;30:383–393
  26. Cleary PA, Orchard TJ, Genuth S, Wong ND, Detrano R, Backlund JY, et al The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC). Study. Diabetes. 2006;55:3556–3565
  27. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;12:405–412
  28. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes. 1999;48:1–9
  29. Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 dia-betic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens. 1993;11:309–317
  30. Strippoli GF, Craig M, Craig JC. Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database Syst Rev. 2005;19:CD004136
  31. Domanski M, Mitchell G, Pfeffer M, Neaton JD, Norman J, Svendsen K, et al Pulse pressure and cardiovascular disease-related mortality: follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 2002;22-29:2677–2683
  32. UK Prospective Diabetes Study Group . Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;12:703–713
  33. Morgensen CE. New treatment guidelines for a patient with diabetes and hypertension. J Hypertens Suppl. 2003;21:S25–S30
  34. Heart Protection Study Collaborative Group . MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;6:7–22
  35. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;21-27:685–696
  36. Costa J, Borges M, David C, Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ. 2006;13:1115–1124
  37. Winell K, Niemi M, Lepäntalo M. The National Hospital Discharge Register data on lower limb Amputations. Eur J Vasc Endovasc Surg. 2006;32:66–70
  38. Gilis-Januszewska A, Szurkowska M, Szybinski K, Glab G, Szybinski Z, Spodaryk K, et al. The efficacy of non-pharmacological intervention in obese patients with newly diagnosed diabetes mellitus type II. Pol Arch Med Wewn. 2001;106:853–860
  39. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;3:1343–1350
  40. Lindstrom J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemio K, et al. Finnish Diabetes Prevention Study Group. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet. 2006;11:1673–1679
  41. Watala C, Golanski J, Pluta J, Boncler M, Rozalski M, Luzak B, et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to meta-bolic control. Thromb Res. 2004;113:101–113
  42. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A PPP Collaborative Group. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic pa-tients: results of the Primary Prevention Project (PPP) trial. Diabetes Care. 2003;26:3264–3272
  43. Meade TW, Brennan PJ. Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ. 2000;321:13–17
  44. Watala C, Pluta J, Golanski J, Rozalski M, Czyz M, Trojanowski Z, et al. Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin. J Mol Med. 2005;83:148–158
  45. Roffi M, Topol EJ. Percutaneous coronary intervention in diabetic patients with non-ST-segment eleva-tion acute coronary syndromes. Eur Heart J. 2004;25:190–198
  46. Ferreira IA, Mocking AI, Feijge MA, Ferreira IA, Mocking AI, Feijge MA, et al. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2006;26:417–422
  47. CAPRIE steering committee . A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet. 1996;348:1329–1339
  48. CURE trial investigators . Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502
  49. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabate M, Jimenez-Quevedo P, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopido-grel treatment. Diabetes. 2005;54:2430–2435
  50. Lepäntalo A, Virtanen KS, Heikkila J, Wartiovaara U, Lassila R. Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions. Eur Heart J. 2004;25:476–483
  51. UK Prospective Diabetes Study (UKPDS) Group . Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;12:854–865
  52. Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with met-formin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2003;(2):CD002967
  53. Thomsen HS, Morcos SK. Contrast media and the kidney: European Society of Urogenital Radiology (ESUR) guidelines. Br J Radiol. 2003;76:513–518
  54. O'Sullivan CJ, Hynes N, Mahendran B, Andrews EJ, Avalos G, Tawfik S, et al. Haemoglobin A1c (HbA1C) in non-diabetic and diabetic vascular patients. Is HbA1C an independent risk factor and predictor of adverse outcome?. Eur J Vasc Endovasc Surg. 2006;32:188–197
  55. Maggio PM, Taheri PA. Perioperative issues: myocardial ischemia and protection–beta-blockade. Surg Clin North Am. 2005;85:1091–1102
  56. Poldermans D, Boersma E, Bax JJ, Thomson IR, van de Ven LL, Blankensteijn JD, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Car-diac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med. 1999;9:1789–1794
  57. Juul AB, Wetterslev J, Gluud C, Kofoed-Enevoldsen A, Jensen G, Callesen T, et al Effect of perioperative beta blockade in patients with diabetes undergoing major non-cardiac surgery: randomised placebo controlled, blinded multicentre trial. BMJ. 2006;24:1482
  58. Kertai MD, Bax JJ, Klein J, Poldermans D. Is there any reason to withhold beta blockers from high-risk patients with coronary artery disease during surgery?. Anesthesiology. 2004;100:4–7
  59. Holstein A, Egberts EH. Traditional contraindications to the use of metformin – more harmful than beneficial?. Dtsch Med Wochenschr. 2006;20:105–110
  60. Soreide E, Eriksson LI, Hirlekar G, Eriksson H, Henneberg SW, Sandin R, et al Pre-operative fasting guidelines: an update. Acta Anaesthesiol Scand. 2005;49:1041–1047
  61. Jermendy G. Clinical consequences of cardiovascular autonomic neuropathy in diabetic patients. Acta Diabetol. 2003;40(Suppl. 2):S370–S374
  62. Hynninen MS, Niemi TT, Poyhia R, Raininko EI, Salmenpera MT, Lepantalo MJ, et al. N-acetylcysteine for the prevention of kidney injury in abdominal aortic surgery: a randomized, double-blind, placebo-controlled trial. Anesth Analg. 2006;102:1638–1645
  63. Lazar HL, Chipkin SR, Fitzgerald CA, Bao Y, Cabral H, Apstein CS. Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events. Circulation. 2004;30:1497–1502
  64. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med. 2001;8:1359–1367
  65. Malmstedt J, Wahlberg E, Jorneskog G, Swedenborg J. Influence of perioperative blood glucose levels on outcome after infrainguinal bypass surgery in patients with diabetes. Br J Surg. 2006;93:1360–1367
  66. Kanji S, Buffie J, Hutton B, Bunting PS, Singh A, McDonald K, et al. Reliability of point-of-care testing for glucose measurement in critically ill adults. Crit Care Med. 2005;33:2778–2785
  67. Furnary AP, Wu Y, Bookin SO. Effect of hyperglycemia and continuous intravenous insulin infusions on outcomes of cardiac surgical procedures: the Portland Diabetic Project. Endocr Pract. 2004;10(Suppl. 2):21–33
  68. Finney SJ, Zekveld C, Elia A, Evans TW. Glucose control and mortality in critically ill patients. JAMA. 2003;15:2041–2047
  69. Carvalho G, Moore A, Qizilbash B, Lachapelle K, Schricker T. Maintenance of normoglycemia during cardiac surgery. Anesth Analg. 2004;99:319–324
  70. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongville J, et al. Third Joint Task Force of the European and other Societes. European Guidelines on Cardiovascular Disease Prevention. Eur J Cardiovasc Preven Rehab. 2003;10(S1):S1–S78
  71. American Diabetes Association . Standards of Medical Care in Diabetes 2007. Diabetes Care. 2007;30(S1):S4–S41

 One of a series of educational articles edited by Janet Powell, UK.

PII: S1078-5884(07)00084-6

doi: 10.1016/j.ejvs.2007.01.012

European Journal of Vascular & Endovascular Surgery
Volume 33, Issue 5 , Pages 583-591 , May 2007

Article Tools